drugset
Drugs / dazdotuftide
last change Jan 2026 re-read 3 minutes ago

dazdotuftide

also known as TRS01 · Dazdotuftida

Small molecule

Developed for
non-infectious anterior uveitis · glaucoma
Investigated by
Tarsier Pharma

Trials 3

today NCT05042609 · Ph 3 NCT04222725 · Ph 1/2 NCT04222712 · Ph 1/2
2020202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/22 trials
Phase 1/2 NCT04222725 Feb → Jul 2020 — Tarsier Pharma Completed No outcome recorded
Phase 1/2 NCT04222712 Feb → Aug 2020 non-infectious anterior uveitis Tarsier Pharma Completed No outcome recorded
Phase 31 trial · 1 missed
Phase 3 NCT05042609 Sep 2021 → Jun 2023 glaucoma, non-infectious anterior uveitis Tarsier Pharma Completed Missed primary

News releases announcing trial results or a regulatory action · 8

DateIssuerRelease
2024-01-17 Tarsier Pharma Regulatory January 16, 2024 tarsierpharma.com ↗
2023-11-15 Tarsier Pharma Regulatory November 13, 2023 tarsierpharma.com ↗
Tarsier Pharma, Ltd., a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing first-in-class new therapies for the treatment of blinding ocular diseases, today announced the successful outcome of a Type C meeting with the U.S. Food and Drug Administration (FDA), supporting the advancement of TRS01 eye drop formulation for the treatment of noninfectious uveitis into a registrational program based on the recently completed TRS4Vision trial.
2023-09-07 Tarsier Pharma Results August 23, 2023 tarsierpharma.com ↗
2023-04-30 Tarsier Pharma Regulatory April 24, 2023 tarsierpharma.com ↗
Tarsier Pharma Ltd., a late-stage pharmaceutical company, announced today that its first-in-class immunomodulator TRS has been granted an International Nonproprietary Name (INN) of ‘Dazdotuftide”‘ and has been placed on the INN Recommended List by the World Health Organization (WHO).
2021-12-06 Tarsier Pharma Results December 2, 2021 tarsierpharma.com ↗
Results showed a statistically significant improvement in signs and symptoms of the disease.
2021-11-08 Tarsier Pharma Results November 8, 2021 tarsierpharma.com ↗
Results showed a statistically significant improvement in the signs and symptoms of the disease, with the high-dose usage being superior to low-dose in a few important measures, such as Anterior Chamber Cells (ACC) clearance, pain resolution, and visual acuity improvement.
2020-10-08 Tarsier Pharma Results October 5, 2020 tarsierpharma.com ↗
Results showed a statistically significant improvement in the signs and symptoms of the disease, with the high-dose usage being superior to low-dose in a few important measures.
2019-09-24 Tarsier Pharma Regulatory Sept. 24, 2019 tarsierpharma.com ↗
Tarsius Pharma today announced the acceptance of its Investigational New Drug (IND) application for TRS01 by the U.S. Food and Drug Administration (FDA).

All press releases naming this drug 8 releases

DateIssuerRelease

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 5 sources stand behind the page.

FieldValueCited text
Known as dazdotuftide “PURPOSE: To evaluate the safety and efficacy of dazdotuftide (TRS01 eye drops), a novel, steroid-free, anti-inflammatory drug in patients with active anterior noninfectious...” PMID 41485727 ↗ Jan 2026
Known as Dazdotuftida ChEMBL registry synonym — accepted as the source's own label CHEMBL5095261 ↗
Known as TRS01 ClinicalTrials.gov intervention name — accepted as the source's own label NCT05042609 ↗
2

NCT04222712 ↗

NCT04222725 ↗
Modality Small molecule — CHEMBL5095261 ↗
Route Topical “TRS01 eye drops” NCT04222712 ↗